Dr Thomas Massey
Projects as PI
- Consultation on the exploitation relating to drug discovery and biomarker development focused on targeting aberrant DNA damage repair to treat neurodegenerative trinucleotide repeat expansion discovery (01/10/2019 - 30/09/2023)
- Identification of coding variants in DNA repair genes affecting age at onset of Huntington's disease (01/08/2016 - 31/10/2017)
- Investigating the effects of GAG repeat structure and MSH3 variants on the molecular biology of Huntington's disease (01/08/2018 - 31/12/2019)
- The role of DNA repair in Huntington's disease pathogenesis: Towards new therapeutic targets (01/08/2016 - 31/07/2019)
- The role of DNA repair in Huntington's disease pathogenesis: towards novel therapeutic targets (01/10/2016 - 30/09/2021)
Projects as Co-Investigator
- A high content analysis platform for analysing dementia-associated genetic variation (10/03/2017 - 09/09/2017)
- An open-label extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ISIS 443139 in Huntington's Disease patients who participated in prior investigational studies of ISIS 443139 (17/04/2018 - 30/04/2020)
- Characterising Genetic Modifiers of Huntington's Disease (01/10/2021 - 30/04/2024)
- Consultation on the exploitation relating to drug discovery and biomarker development focused on targeting aberrant DNA damage repair to treat neurodegenerative trinucleotide repeat expansion discovery (04/10/2019 - 03/10/2023)
- Developing GenOrph-miglustat as a new investigative drug for treating Huntington disease (01/04/2023 - 31/03/2024)